AllianceBernstein’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-22,340
| Closed | -$50.9K | – | 3273 |
|
|
2024
Q2 | $50.9K | Buy |
+22,340
| New | +$85.3K | ﹤0.01% | 3186 |
|
|
2022
Q2 | – | Sell |
-34,400
| Closed | -$261K | – | 3412 |
|
|
2022
Q1 | $261K | Buy |
34,400
+100
| +0.3% | +$948 | ﹤0.01% | 2917 |
|
|
2021
Q4 | $350K | Hold |
34,300
| – | – | ﹤0.01% | 2895 |
|
|
2021
Q3 | $460K | Hold |
34,300
| – | – | ﹤0.01% | 2786 |
|
|
2021
Q2 | $753K | Sell |
34,300
-4,700
| -12% | -$104K | ﹤0.01% | 2641 |
|
|
2021
Q1 | $938K | Buy |
39,000
+15,200
| +64% | +$353K | ﹤0.01% | 2440 |
|
|
2020
Q4 | $428K | Sell |
23,800
-20,300
| -46% | -$303K | ﹤0.01% | 2659 |
|
|
2020
Q3 | $509K | Sell |
44,100
-800
| -2% | -$13.2K | ﹤0.01% | 2517 |
|
|
2020
Q2 | $1.09M | Hold |
44,900
| – | – | ﹤0.01% | 2164 |
|
|
2020
Q1 | $495K | Hold |
44,900
| – | – | ﹤0.01% | 2359 |
|
|
2019
Q4 | $1.19M | Sell |
44,900
-2,600
| -5% | -$60.8K | ﹤0.01% | 2211 |
|
|
2019
Q3 | $1.08M | Hold |
47,500
| – | – | ﹤0.01% | 2217 |
|
|
2019
Q2 | $1.46M | Buy |
47,500
+20,900
| +79% | +$440K | ﹤0.01% | 2144 |
|
|
2019
Q1 | $442K | Sell |
26,600
-2,600
| -9% | -$49.3K | ﹤0.01% | 2569 |
|
|
2018
Q4 | $559K | Sell |
29,200
-700
| -2% | -$26.2K | ﹤0.01% | 2426 |
|
|
2018
Q3 | $1.56M | Hold |
29,900
| – | – | ﹤0.01% | 2105 |
|
|
2018
Q2 | $1.3M | Buy |
+29,900
| New | +$1.28M | ﹤0.01% | 2183 |
|
AllianceBernstein's GTHX Position: Q3 2024 in Review
AllianceBernstein sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 22,340 shares — an estimated $50.9K sold.
AllianceBernstein first reported a position in GTHX in Q2 2018 and held it in 17 quarters. The position peaked at $1.56M in Q3 2018. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- AllianceBernstein reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- AllianceBernstein sold 22,340 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $50.9K.
- AllianceBernstein first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2018 and held it in 17 quarters.
- AllianceBernstein's G1 Therapeutics, Inc. Common Stock position peaked at $1.56M in Q3 2018.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on AllianceBernstein's 13F filing for Q3 2024, filed 14 Nov 2024.